Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. (OLMA): 8 pipeline candidates · 4 upcoming catalysts · ~32 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
31.6 months
D/E 0.10 · 18% dilution
Lead: Approved
8 candidates
4 upcoming, next in ~469d
0 buys · 15 sells (180d)
A transparent, data-derived signal for Olema Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$824.6M
Cash
$52.5M
Quarterly Burn
$46.0M
Runway
31.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| Alpelisib | Phase 1 |
| Atirmociclib | Phase 3 |
| fensolvi kit | Approved |
| OP-1250 | Phase 3 |
| OP-3136 | Phase 1 |
| Palazestrant | Phase 3 |
| palazestrant (formerly known as OP-1250) | Phase 3 |
| palazestrant (OP-1250) | Phase 3 |
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
197
Total value held
$1.30B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 14,216,976 | $212.0M |
| fmr llc | 10,386,845 | $154.9M |
| vanguard capital management llc | 6,167,034 | $92.0M |
| blackrock, inc. | 5,652,135 | $84.3M |
| bvf inc/il | 5,295,893 | $79.0M |
| state street corp | 3,937,831 | $58.7M |
| woodline partners lp | 2,964,060 | $44.2M |
| ra capital management, l.p. | 2,600,000 | $38.8M |
| jennison associates llc | 1,822,123 | $27.2M |
| polar capital holdings plc | 1,602,970 | $23.9M |
Showing top 10 of 197 institutional holders of Olema Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Olema Pharmaceuticals, Inc.'s pipeline?
Olema Pharmaceuticals, Inc. (OLMA) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Olema Pharmaceuticals, Inc.'s lead drug candidate?
Olema Pharmaceuticals, Inc.'s most advanced tracked candidate is Alpelisib (Phase 1) for Metastatic Breast Cancer.
What is Olema Pharmaceuticals, Inc.'s next catalyst?
Olema Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment " — expected September 30, 2027.
What is Olema Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Olema Pharmaceuticals, Inc. has approximately 31.6 months of cash runway.
What is Olema Pharmaceuticals, Inc.'s market capitalization?
Olema Pharmaceuticals, Inc.'s market capitalization is approximately $824.6M.
Get the full picture on Olema Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.